Skip to main content
    P

    PAVmed Inc (PAVM)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $1.63
    +0.29 (+21.73%)

    Market Cap: $13.03M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    PAVmed Inc (PAVM) Earnings: Report Dates and Results

    Updated Nov 13, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    PAVmed (PAVM) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, PAVmed reported EPS of -$0.33, above the -$1.02 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    59%(23/39)
    Avg Surprise
    +8.86%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 29, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.57
    RangeN/A
    4 analysts
    Revenue Consensus
    $132.60K
    Range$58.80K - $210.00K
    4 analysts

    Next Report

    PAVM has an expected report date of Mar 29, 2027.

    PAVM Earnings Call

    The latest PAVM earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, PAVM beat 24, missed 11 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $41000, up 720.0% from $5000 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.33-$1.02N/A+67.65%BeatN/A10 up, 1 downNov 13, 2026$41000
    Jun 30, 2026-$0.42-$0.66N/A+36.36%BeatN/A11 up, 0 downAug 14, 2026$33000
    Mar 31, 2026-$1.17-$0.69-$0.69 - -$0.69-69.57%MissN/A11 up, 0 downMay 15, 2026$22000
    Dec 31, 2025-$1.05-$4.50-$4.50 - -$4.50+76.67%BeatN/A11 up, 0 downMar 26, 2026$52000
    Sep 30, 2025-$0.60-$6.00N/A+90.00%BeatN/A11 up, 0 downNov 13, 2025$5000
    Jun 30, 2025-$1.50-$7.50N/A+80.00%BeatN/A11 up, 0 downAug 14, 2025$6000
    Mar 31, 2025-$0.14-$0.31N/A+54.84%BeatN/A11 up, 0 downMay 15, 2025$8000
    Dec 31, 2024-$0.19-$0.40-$0.40 - -$0.40+52.50%BeatN/A11 up, 0 downMar 25, 2025$10000
    Sep 30, 2024-$16.20-$39.00N/A+58.46%BeatN/A11 up, 0 downNov 13, 2024$996000
    Jun 30, 2024-$6.00-$40.20-$46.85 - -$39.04+85.07%BeatN/A30 up, 0 downAug 13, 2024$979000
    Mar 31, 2024-$2.62-$1.67-$1.82 - -$1.48-56.89%MissN/A31 up, 0 downMay 13, 2024$1.01M
    Dec 31, 2023-$46.92-$53.70-$63.06 - -$44.14+12.63%BeatN/A30 up, 0 downMar 26, 2024$1.05M
    Sep 30, 2023-$37.45-$63.00-$67.53 - -$54.03+40.56%BeatN/A30 up, 0 downNov 14, 2023$791000
    Jun 30, 2023-$46.41-$69.75N/A+33.46%BeatN/A20 up, 0 downAug 15, 2023$166000
    Mar 31, 2023-$54.86-$74.25N/A+26.11%BeatN/A30 up, 0 downMay 16, 2023$446000
    Dec 31, 2022-$0.23-$0.25-$0.26 - -$0.23+8.00%BeatN/A30 up, 0 downMar 14, 2023$112000
    Sep 30, 2022-$67.50-$105.75N/A+36.17%BeatN/A20 up, 0 downNov 15, 2022$76000
    Jun 30, 2022-$76.50-$90.00N/A+15.00%BeatN/AN/A0 up, 0 downAug 16, 2022N/A
    Mar 31, 2022-$63.00-$85.50-$94.55 - -$76.54+26.32%BeatN/A41 up, 0 downMay 12, 2022$189000
    Dec 31, 2021-$0.20-$0.15-$0.16 - -$0.14-33.33%MissN/A20 up, 0 downMar 29, 2022$300000
    Sep 30, 2021-$45.00-$42.75N/A-5.26%MissN/A40 up, 0 downNov 22, 2021$200000
    Jun 30, 2021-$36.00-$40.50N/A+11.11%BeatN/A4N/AAug 12, 2021N/A
    Mar 31, 2021-$36.00-$40.50N/A+11.11%BeatN/A2N/AMay 17, 2021N/A
    Dec 31, 2020-$0.17-$0.11-$0.12 - -$0.11-54.55%MissN/A2N/AFeb 22, 2021N/A
    Sep 30, 2020-$45.00-$49.50-$49.52 - -$45.02+9.09%BeatN/A2N/ANov 17, 2020N/A
    Jun 30, 2020-$58.50-$49.50N/A-18.18%MissN/AN/AN/AAug 18, 2020N/A
    Mar 31, 2020-$148.50-$49.50N/A-200.00%MissN/A1N/AApr 9, 2020N/A
    Dec 31, 2019-$0.19-$0.11-$0.11 - -$0.11-72.73%MissN/A1N/ADec 31, 2019N/A
    Sep 30, 2019-$45.00-$45.00N/A0.00%In lineN/AN/AN/ANov 21, 2019N/A
    Jun 30, 2019-$58.50-$58.50N/A0.00%In lineN/AN/AN/AAug 14, 2019N/A
    Mar 31, 2019-$58.50-$58.50N/A0.00%In line-292600.0%1N/AApr 4, 2019N/A
    Dec 31, 2018-$0.15-$0.14N/A-7.14%MissN/AN/AN/AMar 31, 2019N/A
    Sep 30, 2018-$37.44-$54.00N/A+30.67%BeatN/AN/AN/ANov 15, 2018N/A
    Jun 30, 2018-$54.86-$49.50N/A-10.83%MissN/AN/AN/AAug 14, 2018N/A
    Mar 31, 2018$0.02$0.02N/A0.00%In lineN/AN/AN/AMay 21, 2018N/A
    Sep 30, 2017-$86.76-$63.00N/A-37.71%MissN/AN/AN/ANov 15, 2017N/A
    Jun 30, 2017-$36.00-$63.00N/A+42.86%BeatN/AN/AN/AAug 14, 2017N/A
    Mar 31, 2017-$63.00-$63.00N/A0.00%In lineN/AN/AN/AMay 22, 2017N/A
    Dec 31, 2016-$58.50-$63.00N/A+7.14%BeatN/AN/AN/AFeb 16, 2017N/A
    Sep 30, 2016-$63.00-$67.50N/A+6.67%BeatN/AN/AN/ANov 10, 2016N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.29, after -$25.01 the year before. It was -$121.60 for the year ended Dec 31, 2016, the oldest of the 9 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.29N/A
    Dec 31, 2024-$25.01N/A
    Dec 31, 2023-$185.64N/A
    Dec 31, 2022-$207.23N/A
    Dec 31, 2021-$117.20N/A
    Dec 31, 2020-$252.17N/A
    Dec 31, 2019-$162.19N/A
    Dec 31, 2018-$278.19N/A
    Dec 31, 2016-$121.60N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,100 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,0846
    2026Q2Jun 30, 20263,0966
    2026Q1Mar 31, 20263,5436
    2025Q4Dec 31, 20255,2616
    2025Q3Sep 30, 20254,9315
    2025Q1Mar 31, 20253,0936
    2024Q3Sep 30, 20243,3247
    2024Q2Jun 30, 20243,7517

    2026Q3 Earnings Call

    Opening remarks

    Matthew Riley Vice President, Investor Relations Thank you, operator, and good morning, everyone. Thank you for participating in today's business update call. Joining me today on the call are Dr. Lishan Aklog, Chairman and Chief Executive Officer of PAVmed, along with Dennis McGrath, Chief Financial Officer of PAVmed. The press release announcing our business update and financial results is available on PAVmed's website. Please take a moment to read the disclaimers about forward-looking statements in the press release. The business update press release and conference call include forward-looking statements, and these forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from statements made. Factors that could cause actual results to differ are described in the disclaimer and in our filings with the SEC. For a list and description of these and other important risks and uncertainties that may affect future operations, see Part I, Item 1A, entitled “Risk Factors,” in PAVmed's most recent annual report on Form 10-K filed with the SEC, and any subsequent updates filed in quarterly reports on Forms 10-Q and subsequent Forms 8-K. Except as required by law, PAVmed disclaims any intentions or obligations to publicly update or revise any forward-looking statements to reflect changes in expectations or in events, conditions, or circumstances on which the expectations may be based or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. I would now like to turn the call over to Dr. Lishan Aklog, Chairman and CEO of PAVmed.

    Lishan Aklog Chairman and CEO Thank you, Matt, and good morning, everyone. Thank you for joining our quarterly update call. We're very encouraged by developments across our PAVmed portfolio. The most important development, of course, is that Lucid has secured Medicare reimbursement for EsoGuard, and this is a critical and transformational milestone. On the other front, Veris continues to grow enrollment at Ohio State while advancing its implantable monitor toward FDA submission. We are now actively engaged with the FDA on our two other portfolio units, PortIO and Octeris. We believe this progress puts PAVmed in a strong position to create real long-term shareholder value. Let me start with Lucid. The most significant development at Lucid is that Medicare is now reimbursing EsoGuard. Lucid began submitting claims through its Texas laboratory in late September and has been paid consistently since October at the full Medicare rate. The engagement with the contractor and subsequent consistent pattern constitutes Medicare coverage through claim-by-claim adjudication, and this applies to Medicare patients nationwide. With Medicare reimbursement now secured, Lucid immediately and aggressively transitioned its commercial activity to focus on access to EsoGuard in the Medicare population.

    Frequently Asked Questions About PAVM

    When is PAVmed's next earnings date?

    PAVmed's next earnings report is expected for Mar 29, 2027.

    Did PAVM beat earnings estimates last quarter?

    Yes. PAVmed reported EPS of -$0.33 for the quarter ended Sep 30, 2026, above the -$1.02 estimate, a 67.65% surprise.

    What EPS do analysts expect from PAVM next quarter?

    The consensus EPS estimate for PAVmed for the quarter ending Dec 31, 2026 is -$0.57 from 4 analysts.

    How often does PAVM beat earnings estimates?

    PAVmed beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +48.56%.